Cargando…
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354218/ https://www.ncbi.nlm.nih.gov/pubmed/30733677 http://dx.doi.org/10.3389/fphar.2018.01494 |
_version_ | 1783391143672676352 |
---|---|
author | Li, Yan Huang, Qingying Zhou, Yaoyao He, Meizhi Chen, Jianhong Gao, Yubo Wang, Xue |
author_facet | Li, Yan Huang, Qingying Zhou, Yaoyao He, Meizhi Chen, Jianhong Gao, Yubo Wang, Xue |
author_sort | Li, Yan |
collection | PubMed |
description | Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa. Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I(2) statistic. Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level. Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings. |
format | Online Article Text |
id | pubmed-6354218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63542182019-02-07 The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis Li, Yan Huang, Qingying Zhou, Yaoyao He, Meizhi Chen, Jianhong Gao, Yubo Wang, Xue Front Pharmacol Pharmacology Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa. Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I(2) statistic. Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level. Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings. Frontiers Media S.A. 2019-01-24 /pmc/articles/PMC6354218/ /pubmed/30733677 http://dx.doi.org/10.3389/fphar.2018.01494 Text en Copyright © 2019 Li, Huang, Zhou, He, Chen, Gao and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Yan Huang, Qingying Zhou, Yaoyao He, Meizhi Chen, Jianhong Gao, Yubo Wang, Xue The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title_short | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
title_sort | clinicopathologic and prognostic significance of programmed cell death ligand 1 (pd-l1) expression in patients with prostate cancer: a systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354218/ https://www.ncbi.nlm.nih.gov/pubmed/30733677 http://dx.doi.org/10.3389/fphar.2018.01494 |
work_keys_str_mv | AT liyan theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT huangqingying theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT zhouyaoyao theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT hemeizhi theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT chenjianhong theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT gaoyubo theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT wangxue theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT liyan clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT huangqingying clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT zhouyaoyao clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT hemeizhi clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT chenjianhong clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT gaoyubo clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT wangxue clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis |